Nicola Sgherza

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

Francesca Palandri, Massimo Breccia, Massimiliano Bonifacio et al. · Cancer · 2019 · 149 citations · Full text

Medicine, Hematology, Pharmacology +10

Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission

Monica Bocchia, Anna Sicuranza, Elisabetta Abruzzese et al. · Frontiers in Oncology · 2018 · 105 citations · Full text

Medicine, Hematology, Oncology +17

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice

Carmen Fava, Giovanna Rege‐Cambrin, Irene Dogliotti et al. · Haematologica · 2019 · 77 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9

Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real‐life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart

Giovanni Caocci, Olga Mulas, Elisabetta Abruzzese et al. · Hematological Oncology · 2019 · 70 citations · Full text

Medicine, Cardiology, Hematology +16

Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients

Nicola Polverelli, Giuseppe A. Palumbo, Gianni Binotto et al. · Hematological Oncology · 2018 · 55 citations

Veterinary Medicine, Hematology, Infectious Diseases +17